The battle against TB requires new, faster-acting medicines at affordable prices. The Lilly TB Drug Discovery Initiative, launched in June 2007, is a nonprofit public/private partnership focused on accelerating early-stage TB drug discovery. The initiative is run from a research facility in Seattle, Washington, and operates in partnership with the Infectious Disease Research Institute, Merck and Company, and the National Institute of Allergy and Infectious Diseases, which is part of the U.S. National Institutes of Health. Bringing together specialists from around the world for the systematic exploration of vast, private molecular libraries, the initiative has a primary goal of filling the pipeline with new clinical candidates for future TB drug development.
Lilly has committed more than $20 million to support The Lilly TB Drug Discovery Initiative and opened our library of more than 800,000 existing molecular compounds to test for possible TB treatments, including more effective treatments for drug-resistant strains. In 2008, the initiative announced its first acquisition of compounds for further development into drug candidates.
To learn more, visit: TB Drug Discovery